Mesenchymal stromal cells (MSCs) are multipotent cell populations obtained from fetal and adult tissues. They share some characteristics with limb bud mesodermal cells such as differentiation ...

Human mesenchymal stromal cells (hMSCs) are widely used in cell therapy because of their ease of harvest, self-renewal, and ability to suppress activation of innate and adaptive immune response.

Mesoblast’s Ryoncil ® is the first US FDA-approved mesenchymal stromal cell (MSC) therapy. News release. Mesoblast Limited. December 18, 2024.

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 ...

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of ...

The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL®, indicated for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children ...

Background: Mesenchymal stromal cells (MSCs) have emerged as a potential alternative therapeutic strategy for the prophylaxis of graft-versus-host disease (GVHD) in patients undergoing hematopoietic ...